Specification :

Kanglaite Injection (KLT) is a botanical anticancer drug prepared in emulsion form for intravenous use. It is produced by advanced technology with active substance from a herbal plant "semen coicis".

KLT has the following clinical advantages to cancer patients.
- Effectively kills cancer cells while remarkably improves immune capacity;
- Synergistic function when combined with chemotherapy or radiation therapy;
- Provides high energy nutrition to treat cachexia;
- Markedly relieves cancerous pain;
- Improves QOL, PPT and MST to prolong survival;
- With very slight adverse reaction

KLT has brought great benefits to over 600,000 cancer patients in 2,300 hospitals in China and become the market leader among all anticancer drugs in China in recent 4 years.

Approved by FDA, phase I trial of KLT was conducted in 2001at Huntsman Cancer Institute, Salt Lake City, Utah, USA with inspiring result. Its anti-neoplastic mechanisms have been reconfirmed at Johns Hopkings University, USA.

KLT clinical study in Russia began in January 2002 and ended in April 2003 with satisfactory outcomes. The registration certificate was issued from Russian Ministry of Health in Dec. 2003. KLT was launched in Russia in July 2005 with great success.

We are seeking overseas agents to register, import and distribute KLT with preferential policy. Contact us NOW!